Weekly roundup · generated from the data

M21-1 and 38 CFR changes, week of Oct 10, 2022

1 38 CFR section changed this week. Each change shows the passages added and removed, compared with the previous stored version.

38 CFR

Oct 11, 2022

Added

Requiring either continuous myelosuppressive therapy, or, for six months following hospital admission for any of the following treatments:
peripheral blood or bone marrow stem cell transplant, or chemotherapy, or interferon treatment | 100
If the condition undergoes leukemic transformation, evaluate as leukemia under diagnostic code 7703.
or during the period of treatment with chemotherapy (including myelosuppressants) or interferon treatment.
Any reduction in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter.
87 FR 61248, Oct.

and 2 more added passages

Removed

Requiring either continuous myelosuppressive therapy or, for six months following hospital admission, peripheral blood or bone marrow stem cell transplant, or chemotherapy, or interferon treatment | 100
If the condition undergoes leukemic transformation, evaluate as leukemia under diagnostic code 7703
or during the period of treatment with chemotherapy (including myelosuppressants).
Any reduction in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter

and 1 more removed passages

Ask VA Law Explorer to explain a change and find Board decisions on the same issue.

This page is generated automatically from stored versions of each section. No one writes or edits it, and it adds no interpretation: it shows the passages added and removed.
M21-1 is copied weekly since March 20, 2026, and a change counts only when the VA's own “last updated” date moved; the date shown is that date. 38 CFR versions start December 14, 2016, dated by amendment.
Always confirm the current text at the source link before relying on it.